Brainsway Home

About Us		Technology		Media		Applications		Clinical Trials		Publications		News & Events		Investors

Deep TMS - A unique technology for noninvasive treatment of brain disorders

Initial Focus:

Non-invasive treatment of clinical depression

Breaking News : Brainsway Reports Positive Pivotal Multicenter Major Depression Trial Results

Brainsway Ltd. is pleased to announce positive results from its double-blind multicenter clinical trial for the assessment of the safety and efficacy of Deep Transcranial Magnetic Stimulation ("Deep TMS") with the Company's device (the "H-Coil") in the treatment of major depression. (See "News" for full article).

Click here to download the report (needs Internet Explorer)

The Technology

	Transcranial magnetic stimulation (TMS) is a noninvasive technique used to apply brief magnetic pulses to the brain. The pulses are administered by passing high currents through an electromagnetic coil placed upon the patient's scalp...
More

Applications

	The unique technology of Brainsway Deep TMS enables non-invasive excitation or inhibition of practically any brain structure, in any deep or cortical brain region. Thus, a broad range of brain disorders may potentially be treated with this method.
More

News
18 April, 2012 Brainsway Reports Positive Pivotal Multicenter Major Depression Trial Results
23 February, 2012 2012 Global Neuro-psychiatric Devices New Product Innovation Award to Brainsway
21 February, 2012 Deep TMS to Open the Blood-Brain Barrier in Patients with Brain Tumors
1 January, 2012 Distribution Agreement Signed in Chile

Active Clinical Trials

Major Depression - Prospective Multicenter Double Blind Randomized Controlled Trial to Explore Safety and Efficacy - Study Completed

22 medical centers in the USA, Canada, Europe and Israel

ADHD in adults - Double-Blind Placebo Control Safety and Feasibility Study

Tel Aviv Medical Center, Israel

Obsessive Compulsive Disorder - Double-Blind Placebo Control Safety and Feasibility Study

Sheba Medical Center, Tel Hashomer, Israel

Cocaine Addiction - Double-Blind Placebo Control Safety and Feasibility Study

Columbia University, New York, NY, USA

Tourette Syndrome - Double-Blind Placebo Control Safety and Feasibility Study

Shalvata Mental Health Center, Hod-Hasharon, Israel

Gambling Addiction - Double-Blind Placebo Control Safety and Feasibility Study

Be'er Ya'akov Mental Health Center, Israel

Multiple Sclerosis - Double-Blind Placebo Control Safety and Feasibility Study

Charité University, Berlin, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Smoking Cessation in Chronic Obstructive Pulmonary Disease - Double-Blind Placebo Control Safety and Feasibility Study

Be'er Ya'akov Mental Health Center, Israel

Alzheimer's Disease - Double-Blind Placebo Control Safety and Feasibility Study

Ichilov Medical Center, Tel-Aviv , Israel

Stroke Rehabilitation - Double-Blind Placebo Control Safety and Feasibility Study

Hadassah Medical Organization, Jerusalem, Israel

Autism - Double-Blind Placebo Control Safety and Feasibility Study

The Alfred Hospital and Monash University, Melbourne, Australia

Bipolar Disorder - Double-Blind Placebo Control Safety and Feasibility Study

Shalvata Mental Health Center, Hod-Hasharon, Israel

Schizophrenia Negative Symptoms - Double-Blind Placebo Control Safety and Feasibility Study

Shalvata Mental Health Center, Hod-Hasharon, Israel

Parkinson's Disease - Double-Blind Placebo Control Safety and Feasibility Study

Sheba Medical Center, Tel-Hashomer, Israel

Copyright 2009 @ Brainsway. Address: 19 Hartum st. Bynet Building, 1st floor, Har Hotzvim, Jerusalem, ISRAEL, zip code: 91451 Tel: 972-2-5813140, Fax: 972-2-5812517, Email: infobr@brainsway.com For Italian Issues please contact: Ruggero Nessim Raccah, M.D., ATID Ltd Advanced Technology Innovation Distribution, Rome, Italy. www.atidtech.com Created by Catom.